Migraine as a cerebral ionopathy with abnormal central sensory processing

Neurobiology of Disease

Volumn , Issue , 2007, Pages 333-348

  Ferrari, Michel D ^a   Goadsby, Peter J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884094182     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088592-3/50034-7     Document Type: Chapter

References (122)

1. Goadsby P.J. Pathophysiology of migraine. Migraine and Other Headache Disorders 2006, Marcel Dekker, Taylor & Francis. R.B. Lipton (Ed.).
2. Lance J.W., Goadsby P.J. Mechanism and Management of Headache 2005, Elsevier, New York. 7th edition.
3. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders. Cephalgia 2004, 24:1-160. 1. 2nd edition.
4. Silberstein S.D., Lipton R.B., Goadsby P.J. Headache in Clinical Practice 2002, Martin Dunitz, New York. 2nd edition.
5. Goadsby, P.J., Lipton, R.B., Ferrari, M.D. Migraine: current understanding and treatment. New Engl. J. Med. 2002, 346:257-270.
6. Menken M, Munsat T.L, Toole J.F The global burden of disease study-implications for neurology. Arch. Neurol. 2000, 57:418-420.
7. Andlin-Sobocki P., Jonsson B., Wittchen H.U., Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12(1):1-27.
8. Kruit M.C., van Buchem M.A., Hofman P.A., Bakkers J.T., Terwindt G.M., Ferrari M.D., Launer L.J. Migraine as a risk factor for subclinical brain lesions. JAMA 2004, 291:427-434.
9. Giffin N.J., Ruggiero L., Lipton R.B., Silberstein S.D., Tvedskov J.F., Olesen J., Altman J., Goadsby P.J., Macrae A. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003, 60:935-940.
10. Giffin N.J., Lipton R.B., Silberstein S.D., Tvedskov J.F., Olesen J., Goadsby P.J. The migraine postdrome: an electronic diary study. Cephalalgia 2005, 25:958.
11. Afridi S., Kaube H., Goadsby P.J. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004, 110:675-680.
12. Mogilnicka E, Klimek V. Drugs affecting dopamine neurons and yawning behavior,. Pharmacol. Biochem. Behav. 1977, 7:303-305.
13. Protais P., Dubuc I., Costentin J. Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats. Eur. J. Pharmacol. 1983, 94:271-280. 1983.
14. Serra G, Collu M, Gessa G.L. Dopamine receptors mediating yawning: are they autoreceptors?. Eur. J. Pharmacol. 1986, 120:187-192.
15. Yamada K., Tanaka M., Shibata K, Furukawa T. Involvement of septal and striatal dopamine D-2 receptors in yawning behavior in rats. Psychopharmacology (Berl) 1986, 90:9-13.
16. Blin O, Azulay J, Masson G, Aubrespy G, Serratrice G. Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin. Neuropharmacol. 1991, 14:91-95.
17. del Bene E, Poggonioni M, de Tommasi F. Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 1994, 34:536-538.
18. Levy M.J., Matharu M.S., Goadsby P.J. Prolactinomas, dopamine agonist and headache: two case reports. Eur. J. Neurol. 2003, 10:169-174.
19. Amery W.K., Waelkens J. Prevention of the last chance: an alternative pharmacological treatment of migraine. Headache 1983, 23:37-38.
20. Waelkens J. Domperidone in the prevention of complete classical migraine. Brit. Med. J. 1981, 284:944.
21. Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984, 4:85-90.
22. Levant B, McCarson K.E. D (3) dopamine receptors in rat spinal cord: implications for sensory and motor function. Neurosci. Lett. 2001, 303:9-12.
23. Levey A.I., Hersch S.M., Rye D.B., Sunahara R.K., Niznik H.B., Kitt C.A., Price D.L., Maggio R., Brann M.R., Ciliax B.J., et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. USA 1993, 90:8861-8865.
24. van Dijken H., Dijk J., Voom P, Holstege J.C. Local-ization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur. J. Neurosci. 1996, 8:621-628.
25. Bergerot A., Goadsby P.J. Distribution of the dopamine D1 and D2 receptors in the rat trigeminocervical complex. Cepha-lalgia 2005, 25:872.
26. Bergerot A., Storer R.J., Goadsby P.J. Dopamine inhibits trigeminovascular transmission in the rat. Cephalalgia 2005, 25:862.
27. Skagerberg G., Bjorklund A., Lindvall O., Schmidt R.H. Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain. Res. Bull. 1982, 9:237-244.
28. Fleetwood-Walker S.M., Hope P.J., Mitchell R. Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J. Physiol. 1988, 399:335-348.
29. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994, 117:199-210.
30. Goadsby P.J. Migraine, aura, and cortical spreading depres-sion: why are we still talking about it?. Ann. Neurol. 2001, 49:4-6.
31. Goadsby P.J. Can we develop neurally acting drugs for the treatment of migraine?. Nature Rev. Drug Discov. 2005, 4:741-750.
32. Akerman S., Goadsby P.J. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuro. Report 2005, 16:1383-1387.
33. Tvedskov J.F., Thomsen L.L., Iversen H.K., Williams P., Gibson A., Jenkins K., Peck R., Olesen J. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia 2004, 24:1076-1087.
34. Tvedskov J.F., Thomsen L.L, Iversen H.K., Gibson A., Williams P., Olesen J. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia 2004, 24:576-585.
35. Storer R.J., Goadsby P.J. Topiramate inhibits trigemi-novascular neurons in the cat. Cephalalgia 2004, 24:1049-1056.
36. Storer R.J., Goadsby P.J. Topiramate has a locus of action outside of the trigeminocervical complex. Cephalalgia 2005, 25:934.
37. Wolff H.G Headache and Other Head Pain 1963, Oxford University Press, London. 3rd edition.
38. Moskowitz M.A., Cutrer F.M. Sumatriptan: a receptor-targeted treatment for migraine. Ann. Rev. Med. 1993, 44:145-154.
39. Dimitriadou V., Buzzi M.G., Moskowitz M.A., Theoharides T.C. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991, 44:97-112.
40. Dimitriadou V., Buzzi M.G., Theoharides T.C., Moskowitz M.A. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992, 48:187-203.
41. Bolay H., Reuter U., Dunn A.K., Huang Z., Boas D.A., Moskowitz M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Med. 2002, 8:136-142.
42. May A., Shepheard S., Wessing A., Hargreaves R.J., Goadsby P.J., Diener H.C. Retinal plasma extrava-sation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain 1998, 121:1231-1237.
43. May A., Goadsby P.J. Substance P-receptor antagonists in the therapy of migraine. Expert Op. Investigat. Drug 2001, 10:1-6.
44. Peroutka S.J. Neurogenic inflammation and migraine: impli-cations for therapeutics. Molecul. Intervent. 2005, 5:306-313.
45. Selby G., Lance J.W. Observations on 500 cases of migraine and allied vascular headache. J. Neurol. Neurosurg. Psychiat. 1960, 23:23-32.
46. Burstein R., Yarnitsky D., Goor-Aryeh I., Ransil B.J., Bajwa Z.H. An association between migraine and cutaneous allodynia. Ann. Neurol. 2000, 47:614-624.
47. Hoskin K.L., Kaube H., Goadsby P.J. Central acti-vation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain 1996, 119:249-256.
48. Pozo-Rosich P., Oshinsky M. Effect of dihydroergo-tamine (DHE) on central sensitisation of neurons in the trigeminal nucleus caudalis. Neurology 2005), 64(1):A151.
49. May A., Goadsby P.J. The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J. Cerebr. Blood Flow Metabol. 1999, 19:115-127.
50. Olesen J., Diener H.-C., Husstedt I.-W., Goadsby P.J., Hall D., Meier U., Pollentier S., Lesko L.M. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effec-tive in the treatment of migraine attacks. New Engl. J. Med. 2004, 350:1104-1110.
51. Bartsch T., Goadsby P.J. Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. Headache Currents 2005, 2:42-48.
52. Goadsby P.J. New targets in the acute treatment of headache. Curr. Opin. Neurol. 2005, 18:283-288.
53. Goadsby P.J. Prejunctional and presynaptic trigeminovas-cular targets: what preclinical evidence is there?. Headache Currents 2004, 1:1-6.
54. Cohen A.S., Goadsby P.J. Functional neuroimaging of primary headache disorders. Curr. Neurol. Neurosci. Rep. 2004, 4:105-110.
55. Goadsby P.J., Lambert G.A., Lance J.W. Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Res. 1982, 249:247-254.
56. Kaube H., Giffin N.J. The electrophysiology of migraine. Curr. Opin. Neurol. 2002, 15:303-309.
57. Schoenen J., Ambrosini A., Sandor P.S., Maertens de Noordhout A. Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their patho-physiologic significance. Clin. Neurophys. 2003, 114:955-972.
58. Niebur E., Hsiao S.S., Johnson K.O. Synchrony: a neural mechanism for attentional selection?. Curr. Opin. Neurobiol. 2002, 12:190-194.
59. Ferrari M.D. Migraine. Lancet 1998, 351:1043-1051.
60. Kors E.E., Vanmolkot K.R., Haan J., Frants R.R., van den Maagdenberg A.M., Ferrari MD. Recent findings in headache genetics. Curr. Opin. Neurol. 2004, 17:283-288.
61. Ducros A., Denier C., Joutel A., Cecillon M., Lescoat C., Vahedi K., Darcel F., Vicaut E., Bousser M.G., Tournier-Lasserve E. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. New Engl. J. Med. 2001, 345:17-24.
62. Terwindt G.M., Ophoff R.A., Haan J., Vergouwe M.N., van Eijk R., Frants R.R., Ferrari M.D. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Neurology 1998, 50:1105-1110.
63. 2+channel gene CACNL1A4. Cell 1996, 87:543-552.
64. 2+channels and their role in neurotransmitter release. Cell Calcium 1998, 24:307-323.
65. Haan J., Kors E.E., Vanmolkot K.R., van den Maagdenberg A.M., Frants R.R., Ferrari M.D. Migraine genetics: an update. Curr. Pain. Headache Rep. 2005, 9:213-220.
66. +pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nature Genetics 2003, 33:192-196.
67. +-ATPase pump gene ATP1A2 asso-ciated with familial hemiplegic migraine and benign familial infantile convulsions. Ann. Neurol. 2003, 54:360-366.
68. Ambrosini A., D'Onofrio M., Grieco G.S., Di Mambro A., Fortini D., Nicoletti F., Nappi G., Sances G., Schoenen J., Buzzi M.G., Santorelli F.M., Pierelli F. A new muta-tion on the ATPA2 gene in one Italian family with basilar-type migraine linked to the FHM2 locus. Neurology 2005, 64(1):A132.
69. Dichgans M., Freilinger T., Eckstein G., Babini E., Lorenz-Depiereux B., Biskup S., Ferrari M.D., Herzog J., van den Maagdenberg A.M., Pusch M., Strom T.M. Mutation in the neuronal voltage-gated sodium channel SCN1Acauses familial hemiplegic migraine. Lancet 2005, 366:371-377.
70. Vanmolkot, K., et al. Unpublished data.
71. Thomsen L.L., Ostergaard E., Olesen J., Russell M.B. Evidence for a separate type of migraine with aura: sporadic hemi-plegic migraine. Neurology 2003, 60:595-601.
72. Thomsen L.L., Ostergaard E., Romer S.F., Andersen I., Eriksen M.K., Olesen J., Russell M.B. Sporadic hemiplegic migraine is an aetiologically heterogeneous disorder. Cephalalgia 2003, 23:921-928.
73. Terwindt G., Kors E., Haan J., Vermeulen F., van den Maagdenberg A., Frants R., Ferrari M. Mutation anal-ysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch. Neurol. 2002, 59:1016-1018.
74. deVries et al. Unpublished data.
75. Lehmann-Horn, F., and Ferrari, M.D. (1997). International Headache Congress HIS, Amsterdam.
76. Sandor P.S., Mascia A., Seidel L., de Pasqua V., Schoenen J. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann. Neurol. 2001, 49:668-672.
77. 2+channel blocker, inhibits neurogenic vasodilation and extrava-sation following electrical stimulation of trigeminal ganglion. Brain Res. 2000, 873:94-101.
78. Knight Y.E., Bartsch T., Kaube H., Goadsby P.J. J. P/Q-type calcium channel blockade in the PAG facilitates trigem-inal nociception: a functional genetic link for migraine. J. Neurosci. 2002, 22(213):1-6.
79. Shields K.G., Storer R.J., Akerman S., Goadsby P.J. Calcium channels modulate nociceptive transmission in the trigem-inal nucleus of the cat. Neuroscience 2005, 135:203-212.
80. Jouvenceau A., Eunson L.H., Spauschus A., Ramesh V., Zuberi S.M., Kullmann D.M., Hanna M.G. Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet 2001, 358:801-807.
81. Imbrici P., Jaffe S.L., Eunson L.H., Davies N.P., Herd C., Robertson R., Kullmann D.M., Hanna M.G. Dysfunc-tion of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain 2004, 127:2682-2692.
82. 2+channelopathy. Neuron 2004, 43:387-400.
83. Hans M., Luvisetto S., Williams M.E., Spagnolo M., Urrutia A., Tottene A., Brust P.F., Johnson E.C., Harpold M.M., Staud-erman K.A., Pietrobon D. Functional consequences of mutations in the human alpha (1A) calcium channel subunit linked to familial hemiplegic migraine. J. Neurosci. 1999, 19:1610-1619.
84. 2+channel kinetics. J. Biol. Chem. 1998, 273:5586-5590.
85. Kraus R.L., Sinnegger M.J., Koschak A., Glossmann H., Stenirri S., Carrera P., Striessnig J. Three new familial hemiplegic migraine mutants affect P/Q-type Ca (2+) channel kinetics. J. Biol. Chem. 2000, 275:9239-9243.
86. V2.1 current density in neurons. Proc. Natl. Acad. Sci. USA 2002, 99:13284-13289.
87. van den Maagdenberg A.M., Pietrobon D., Pizzorusso T., Kaja S., Broos L.A., Cesetti T., van de Ven R.C., Tottene A., van der Kaa J., Plomp J.J., Frants R.R., Ferrari M.D. A Cacna1a knockin migraine mouse model with increased suscepti-bility to cortical spreading depression. Neuron 2004, 41:701-710.
88. Segall L., Mezzetti A., Scanzano R., Gargus J.J., Purisima E., Blostein R. Alterations in the alpha2 isoform of Na,K-ATPase associated with familial hemiplegic migraine type 2. Proc. Natl. Acad. Sci USA 2005, 102:11106-11111.
89. Ikeda K., Onimaru H., Yamada J., Inoue K., Ueno S., Onaka T., Toyoda H., Arata A., Ishikawa T.O., Taketo M.M., Fukuda A., Kawakami K. Malfunction of respiratory-related neuronal activity in Na+, K+-ATPase alpha2 subunit-deficient mice is attributable to abnormal Cl-homeostasis in brainstem n. J. Neurosci. 2004, 24:10693-10701.
90. James P.F., Grupp I.L., Grupp G., Woo A.L., Askew G.R., Croyle M.L., Walsh R.A., Lingrel J.B. Identification of a specific role for the Na,K-ATPase alpha 2 isoform as a regulator of calcium in the heart. Mol. Cell 1999, 3:555-563.
91. Moskowitz M.A., Bolay H., Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine geno-types. Ann. Neurol. 2004, 55:276-280.
92. Pietroben, D., et al. Unpublished data.
93. Tournier-Lasserve E., Joutel A., Melki J., Weissenbach J., Lathrop G.M., Chabriat H., Mas J.L., Cabanis E.A., Baudrimont M., Maciazek J., Bach M.A., Bousser M-G. Cere-bral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19p12. Nature Genetics 1993, 3:256-259.
94. Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., Alamowitch S., Domenga V., Cecillion M., Marechal E., Maciazek J., Vayssiere C., Cruaud C., Cabanis E.A., Ruchoux M.M., Weissenbach J., Bach J.F., Bousser M.G., Tournier-Lasserve E. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383:707-710.
95. Domenga V., Fardoux P., Lacombe P., Monet M., Maciazek J., Krebs L.T., Klonjkowski B., Berrou E., Mericskay M., Li Z., Tournier-Lasserve E., Gridley T., Joutel A. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 2004, 18:2730-2735.
96. Ruchoux M.M., Domenga V., Brulin P., Maciazek J., Limol S., Tournier-Lasserve E., Joutel A. Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and. Am. J. Pathol. 2003, 162:329-342.
97. Lundkvist J., Zhu S., Hansson E.M., Schweinhardt P., Miao Q., Paul Beatus P., Dannaeus K., Karlström H., Johansson C.B., Viitanen M., Rozell B., Spenger C., Mohammed A., Kalimo H., Lendahl L. Mice carrying a R142C Notch 3 knock-in mutation do not develop a CADASIL-like phenotype. Genesis 2005, 41:13-22.
98. Terwindt G.M., Haan J., Ophoff R.A., Groenen S.M., Storimans C.W., Lanser J.B., Roos R.A., Bleeker-Wagemakers E.M., Frants R.R., Ferrari M.D. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain 1998, 121:303-316.
99. Ophoff R.A., DeYoung J., Service S.K., Joosse M., Caffo N.A., Sandkuijl L.A., Terwindt G.M., Haan J., van den Maagdenberg A.M., Jen J., Baloh R.W., Barilla-LaBarca M.L., Saccone N.L., Atkinson J.P., Ferrari M.D., Freimer N.B., Frants R.R. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy and stroke map to a single locus on. Am. J. Hum. Genet. 2001, 69:447-453.
100. Hottenga J.J., Vanmolkot K.R., Kors E.E., Kheradmand Kia S., de Jong P.T., Haan J., Terwindt G.M., Frants R.R., Ferrari M.D., van den Maagdenberg A.M. The 3p21.1-p21.3 hered-itary vascular retinopathy locus increases the risk for Raynaud's phenomenon and migraine. Cephalalgia 2005, 25:1168-1172.
101. Carlsson A., Forsgren L., Nylander P.O., Hellman U., Forsman-Semb K., Holmgren G., Holmberg D., Holmberg M. Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1. Neurology 2002, 59:1804-1807.
102. Nyholt D.R., Morley K.I., Ferreira M.A., Medland S.E., Boomsma D.I., Heath A.C., Merikangas K.R., Montgomery G.W., Martin N.G. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am. J. Hum. Genet. 2005, 77:500-512.
103. Wessman M., Kallela M., Kaunisto M.A., Marttila P., Sobel E., Hartiala J., Oswell G., Leal S.M., Papp J.C., Hamalainen E., Broas P., Joslyn G., Hovatta I., Hiekkalinna T., Kaprio J., Ott J., Cantor R.M., Zwart J.A., Ilmavirta M., Havanka H., Farkkila M., Peltonen L., Palotie A. A susceptibility locus for migraine with aura, on chromosome 4q24. 2002, 70:652-662.
104. Bjornsson Gudmundsson A., Gudfinnsson G., Bjornsson E., Gudmundsson A., Gudfinnsson G., Hrafnsdottir E., Benedikz M., Skuladottir J., Kristjansson S., Frigge K.M.L., Kong A., Stefansson K., Gulcher J.R. Localization of a gene for migraine without aura to chromosome 4q21. Am. J. Hum. Genet. 2003, 73:986-993.
105. Cader Z.M., Noble-Topham S., Dyment D.A., Cherny S.S., Brown J.D., Rice G.P., Ebers G.C. Significant linkage to migraine with aura on chromosome 11q24. Hum. Mol. Genet. 2003, 12:2511-2517.
106. Soragna D., Vettori A., Carraio G., Marchioni E., Vazza G., Bellini S., Tupler R., Savoldi F., Mostacciuolo M.L. A locus for migraine without aura maps on chromosome 14q21.2-q22.3. Am. J. Hum. Genet. 2003, 72:161-167.
107. Nyholt D.R., Dawkins J.L., Brimage P.J., Goadsby P.J., Nicholson G.A., Griffiths L.R. Evidence for an X-linked genetic component in familial typical migraine. Hum. Mol. Genet. 1998, 7:459-463.
108. Russo L., Mariotti P., Sangiorgi E., Russo L., Mariotti P., Sangiorgi E., Giordano T., Ricci I., Lupi F., Chiera R., Guzzetta F., Neri G., Gurrieri F. A new suscepti-bility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am. J. Hum. Genet. 2005, 76:327-333.
109. Lea R.A., Nyholt D.R., Curtain R.P., Ovcaric M., Sciascia R., Bellis C., Macmillan J., Quinlan S., Gibson R.A., McCarthy L.C., Riley J.H., Smithies Y.J., Kinrade S., Griffiths L.R. A genome-wide scan provides evidence for loci influencing a severe heritable form of common migraine. Neurogenetics 2005, 6:67-72.
110. Montagna P., Pierangeli G., Cevoli S., Mochi M., Cortelli P. Pharmacogenetics of headache treatment. Neurologic. Sci. 2005, 26(2):S143-S147.
111. Kowa H., Yasui K., Takeshima T., Urakami K., Sakai F., Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am. J. Med. Genet. 2000, 96:762-764.
112. Kara I., Sazci A., Ergul E., Kaya G., Kilic G. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res. Mol. Brain Res. 2003, 111:84-90.
113. Lea R.A., Ovcaric M., Sundholm J., MacMillan J., Griffiths L.R. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med. 2004, 2:3.
114. Oterino A., Valle N., Bravo Y., Munoz P., Sanchez-Velasco P., Ruiz-Alegria C., Castillo J., Leyva-Cobian F., Vadillo A., Pascual J. MTHFR T677 homozygosis influences the pres-ence of aura in migraineurs. Cephalalgia 2004, 24:491-494.
115. Scher A.I., Terwindt G.M., Verschuren W.M., Kruit M.C., Blom H.J., Kowa H., Frants R.R., van den Maagdenberg A.M., van Buchem M., Ferrari M.D., Launer L.J. Migraine and MTHFR C677T genotype in a population-based sample. Ann. Neurol. 2006, 59:372-375.
116. Lea R.A., Ovcaric M., Sundholm J., Solyom L., Macmillan J., Griffiths L.R. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combi-nation to increase migraine susceptibility. Brain Res. Mol. Brain Res. 2005, 136:112-117.
117. Colson N.J., Lea R.A., Quinlan S., MacMillan J., Griffiths L.R. Investigation of hormone receptor genes in migraine. Neurogenetics 2005, 6:17-23.
118. Trabace S., Brioli G., Lulli P., Morellini M., Giacovazzo M., Cicciarelli G., Martelletti P. Tumor necrosis factor gene polymorphism in migraine. Headache 2002, 42:341-345.
119. Rainero I., Grimaldi L.M., Salani G., Valfre W., Rivoiro C., Savi L., Pinessi L. Association between the tumor necrosis factor-alpha-308 G/A gene polymorphism and migraine. Neurology 2004, 62:141-143.
120. Paterna S., Di Pasquale P., D'Angelo A., Seidita G., Tuttolomondo A., Cardinale A., Maniscalchi T., Follone G., Giubilato A., Tarantello M., Licata G. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without a. Eur. Neurol. 2000, 43:133-136.
121. Kowa H, Fusayasu E, Ijiri T, Ishizaki K, Yasui K, Nakaso K, Kusumi M, Takeshima T, Nakashima K. Asso-ciation of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci. Lett. 2005, 374:129-131.
122. Lin J.J., Wang P.J., Chen C.H., Yueh K.C., Lin S.Z., Harn H.J. Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man. Acta. Neurol. Taiwan 2005, 14:120-125.